KMCSHIL137.80

K M C Speciality Hospitals (India) Limited

· Pharma & Health
₹ CrorePeersDRAGARWQKOVAILOTUSEYEGPTHEALTHGKSLSHALBYINDRAMEDCOARTEMISMED
Comp Set
In ₹ Crore except Per Share
Latest Annual
KMCSHIL
FY24
DRAGARWQ
FY26
KOVAI
FY20
LOTUSEYE
FY26
Peer
Median
Valuation — at last close
P/E74.09×36.06×73.46×2812.50×73.46× +1%
P/B3.89×3.89×
EV/EBITDA72.00×72.00×
Market Cap₹234 Cr₹234 Cr
Growth
Revenue CAGR 3Y19.96%20.68%4.52%12.60% +58%
Revenue CAGR 5Y22.59%10.66%16.63%
Net Income CAGR 3Y33.46%23.83%-72.98%-24.58% +236%
Revenue YoY (latest Q)26.19%26.19%
Net Income YoY (latest Q)12.65%12.65%
Profitability
EBITDA Margin26.75%30.86%23.61%6.30%23.61% +13%
Net Income Margin17.15%14.89%13.29%0.15%13.29% +29%
Return on Common Equity20.24%21.94%0.13%20.24%
Return on Capital Employed15.21%10.47%-0.50%10.47%
Return on Assets9.15%8.54%0.10%8.54%
Credit & Quality
Total Debt/Equity0.24×1.18×0.19×0.24×
Interest Coverage32.79×8.39×7.93×-0.43×7.93× +313%
Scale — latest FY
Revenue / Total Income₹177 Cr₹471 Cr₹712 Cr₹53.7 Cr₹471 Cr -62%
Net Income₹30.4 Cr₹70.1 Cr₹94.6 Cr₹0.1 Cr₹70.1 Cr -57%
Total Assets₹766 Cr₹1,107 Cr₹82.6 Cr₹766 Cr
EPS₹1.86₹147.02₹86.44₹0.04₹86.44 -98%
Book Value per Share₹28.92₹28.92
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.